NOVO SEEDS | In 2017, Novo Seeds celebrated its 10th anniversary. It added four companies to the portfolio, had several companies reach clinical stage development and carried out its first IPO. Investment activity across the portfolio underscores Novo Seeds’ ability to transform biological insights into successful biotech startups.

“2017 was a good year. We continued to play a key role in developing the Nordic life science industry. We built four companies and invested significant capital in our portfolio companies on their paths to developing new drugs,” says Søren Møller, Managing Partner, Novo Seeds.

The new investments saw the value of the 21 companies in Novo Seeds’ portfolio increase by 50%, and external investors accounted for three quarters of the investment in each portfolio company.